Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic

Background In Australia, tixagevimab/cilgavimab 150 mg/150 mg was a government-funded pre-exposure prophylaxis for COVID-19 people with multiple sclerosis (pwMS) and other neuroimmunological conditions (pwNIc) treated with anti-CD20 antibodies or sphingosine-1-phosphate receptor modulators were elig...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Helmut Butzkueven, Wei Zhen Yeh, Mastura Monif, Robb Wesselingh, Louise Rath, Olga Skibina, Cassie Nesbitt, Nabil Seery, Anneke van der Walt, Francesca Bridge, Michael Zhong, Tracie Tan, Angie Roldan, YiChao Foong
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMJ Publishing Group 2024-04-01
Serie:	BMJ Neurology Open
Accesso online:	https://neurologyopen.bmj.com/content/6/1/e000667.full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!